Myocardial uptake of radioactively labelled free fatty acids by Westera, G & Visser, F C
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 1985
Myocardial uptake of radioactively labelled free fatty acids
Westera, G; Visser, F C
Abstract: Structural variations in the carbon chain of free fatty acids influence the uptake of free fatty
acids in the myocardium. To enable the use of free fatty acids in nuclear cardiology, various methods
of introducing gammaemitting isotopes have been evaluated. The uptake of various free fatty acids is
described and structure-activity relationships deduced
DOI: https://doi.org/10.1093/eurheartj/6.suppl_b.3
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-154110
Journal Article
Published Version
Originally published at:
Westera, G; Visser, F C (1985). Myocardial uptake of radioactively labelled free fatty acids. European
Heart Journal, 6(Suppl B):3-12.
DOI: https://doi.org/10.1093/eurheartj/6.suppl_b.3
European Heart Journal (1985) 6 (Supplement B), 3-12
Myocardial uptake of radioactively labelled
free fatty acids
G. WESTERA* AND F. C. VlSSERf
* Department of Nuclear Medicine, University Hospital, Rdmistrasse 100, 8091 Zurich, Switzerland and
^Department of Cardiology, Free University Hospital, De Boelelaan 1117, 1007 MB Amsterdam, The
Netherlands
KEY WORDS: Myocardial uptake, free fatty acids.
Structural variations in the carbon chain of free fatty acids influence the uptake of free fatty acids in the
myocardium. To enable the use of free fatty acids in nuclear cardiology, various methods of introducing gamma-
emitting isotopes have been evaluated.
The uptake of various free fatty acids is described and structure-activity relationships deduced.
Introduction
In the search for a tracer substance to monitor fatty
acid metabolism in the heart by myocardial
scintigraphy, several different free fatty acids
('unesterified fatty acid', FFAs) analogues have been
described.
Three factors are of prime importance, when
judging the value of any radiopharmaceutical:
(a) the uptake in the target organ (also in relation to
the uptake in other tissues),
(b) the residence time/elimination rate of the
compound in/from the target organ,
(c) the biochemical pathway by which the com-
pound is metabolized in the body.
The last two aspects are dealt with by authors in
other contributions to this supplement, and will only
be mentioned here when it is pertinent to the
'uptake' process. Thus, only FFAs, which have been
labelled with gamma-emitting radionuclides and for
which pertinent uptake data are available will be
discussed here.
'Normal' FFAs labelled with Carbon-11
"C-labelled fatty acids (which are chemically
indistinguishable from naturally occurring FFAs)
have been studied in nuclear cardiology mainly to
demonstrate their use in positron-emission
tomography. Attention has been focussed on the
dynamic behaviour of these compounds (their
clearance from the heart) and mostly only qualitative
measures of their uptake have been obtained"'2 '.
Myocardial uptake has been measured as the
extraction fraction in dogs and rabbits and as the
percentage of the injected dose per gram of tissue
(% i.d. g" ' ) in rats and mice (Table 1(3"9)).
The amount of data given in Table 1 hardly allow
any conclusions, although there is general agreement
with conclusions from other studies which will be
discussed below.
Because of the need for a cyclotron to produce U C
(which has a 20-min half life) and for a positron
camera to detect this nuclide, a search for FFAs
labelled with other nuclides has been in progress
from the start. Focus has been on radiohalogenated
and particularly radioiodinated compounds.
FFAs labelled along the carbon chain
The first attempt to visualize the heart using
radiolabelled FFAs was with oleic acid, iodinated
over the double bond ( 1 0 t l l ) . Thus a product is
obtained labelled in the middle of the carbon chain
and with the bulky iodine in this position,
myocardial uptake was relatively low*3'12'. The
introduction of the smaller fluorine-18 atom in the
same position did not influence uptake (Table 2(13)).
This indicates that for a substituent in the middle of
the carbon chain its size determines the influence on
myocardial uptake.
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Table I Myocardial uptake of FFAs labelled with lxCorl*C
FFA
l-"C-stearic acid
l-"C-oleic acid
l-"C-palmitic acid
16-'*C-palmitic acid
l-"C-octanoic acid
l-"C-propanoic acid
l-l4C-acetic acid
Animal
dog
dog
dog
rabbit
mouse
rat
rabbit
mouse
dog
Uptake
70%
61%
52%
23%
43% Ld. g" 1
2-6% i.d. g">
56%
60% ' '
Time (min)
<O5
5
10
Ref.
3
3
4
5
6
7
4
8
9
The following apply in the tables in this paper
% extraction fraction.
% i.d. percentage of injected dose in total organ.
% i.d. g~' percentage of injected dose per gram of organ.
% kg d. g"1 percentage of injected dose per gram of organ divided by body weight in
kg.
Time Time after injection of uptake given in min (unless otherwise stated). Where
possible the maximum uptake with its time after injection will be given.
Maximum uptake in mice and rats is in less than O5-1-0 min.
FFA Free (unestenfied) fatty acid.
The introduction of tellurium as a link in the
carbon chain can be compared to the presence of a
double bond<14).
The effect of a (non-radioactive) methyl substituent
along the chain will be treated separately (Table 8).
Labelling in the 2-position
Another way to influence biological behaviour of
FFAs is to introduce a substituent on the carbon
atom neighbouring the acid function (that is next to
the COOH- group: the 2- or alpha-position).
Halogens have been introduced there, with
considerable reduction of myocardial uptake
(Table 3(6>'3)). An electrophilic substituent in the
2-position makes the organic acid stronger (i.e. more
apt to dissociate its H+) and thus more hydrophilic
('water loving'). Especially fluorine and (to a lesser
extent) chlorine will exert their influence via such a
mechanism. This effect becomes less pronounced for
Table 2 Uptake in the heart of FFAs labelled in the middle of the carbon chain (for abbreviations
see Table 1)
FFA
l-uC-oleic acid
9,10-13lI-hexadecanoic* acid
l-'*C-oleic acid
"
31I-oleicacid'
'
13lI-linoleic acid'
l-"C-palmitic acid
9,10-l8F-stearic acid
9-l23mTe-tellura-heptadecanoic acid
Animal
dog
dog
rat
rat
dog (LV)f
dog
rat
dog (LV)f
dog
mouse
mouse
rat
mouse
mouse
Uptake
61%
33%
3-42% i.d. g~'
1-78% i.d. g"1
0035% i.d. g~'
0060% i.d. g"1
1-34% i.d. g - 1
0034% L d g - 1
0-026% i.d. g~'
43% i.d. g"1
43% i.d. g"1
3-7% i.d. g"1
30-5% i.d. g"1
25%Ld.g - '
Time (min)
5
5
5
30
5
5
30
<0-5
0-5
30
5
60
Ref.
3
3
12
12
12
12
12
12
12
6
13
14
14
14
• Iodinated linoleic and linolenic acid gave results, indistinguishable from iodinated oleic acid'31.
t LV: the uptake in the left ventricle (LV) is given. Right ventricular uptake was comparable. Atrial
uptake tended to be less.
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Table 3 Myocardial uptake of 2-substituted FFAs (for units see Table I)
FFA
l-"C-stearic acid
2-19F-stearic acid
2-3*mCl-stearic acid
2-77Br-stearic acid
2-l23I-stearic acid
2-13'I-hexadecanoic acid
Animal
mouse
mouse
mouse
mouse
mouse
mouse
Uptake
43% i.d. g"
11% Ld. g"
23% i.d. g"
15% i.d. g"
14% i.d. g-
20% i.d. g"
Time (min)
< 0 5
0-5
1-5
0-5
1-5
<1
Ref.
6
6
6
6
6
15
the larger halogens bromine and iodine, but then the
steric effect becomes more important and the heart
uptake of 2-iodo- and 2-bromo-FFAs was found to
be rather low*61".
Labelling in the omega-position
Because the uptake of the 'iodinated oleic acid'
was less satisfactory, it was proposed*3' to label
FFAs at the end of the carbon chain, where it would
affect the stereochemistry of the carbon chain to the
least extent. And if the halogen-label was to be
iodine, its size would match that of a methyl group
and moreover little polarization of the terminal
carbon-halogen bond (C-X-bond) would occur with
accompanying little effect on the lipofilicity. It was
thus found (Table 4<615"22)) that omega-iodinated
compounds are taken up by the myocardium to
about the same extent as 'normal' FFAs.
If the label is the more polarizing halogen bromine
or chlorine, omega-labelled FFAs are taken up
less(6); this effect has for F been offset by its small
size: the uptake of a fluoro-compound equals that of
an unlabelled FFA(13).
As a result of these findings, labelling of FFAs is
now almost exclusively in the omega-position.
The influence of unsaturation
The presence of a double bond in the carbon chain
does not seem notably to influence the uptake of an
FFA in the heart (Table 50.1s.19.">) although the
results of different groups are not very consistent.
Thus our finding'19) that there is a significantly
different uptake between the 17- and 18-carbon
analogues (16-I-hexadecenoic acid and 17-1-
heptadecanoic acid) is the consequence of the
number of C-atorris rather than of the unsaturation
in the 16-I-hexadecenoic acid.
Again (as with the saturated FFAs) bromo-
instead of iodo-labelling reduces uptake con-
siderably'15).
Contrary to the effect of a double bond, a triple
bond (15 '17>22) reduces myocardial uptake con-
siderably. This is a consequence of the more
stringent stereochemical requirements imposed on
the carbon chain by a triple compared with a double
bond. Also the electronic configuration around a
Table 4 Uptake in the heart of omega-halogenaled straight chain saturated FFAs with
16-18 C-atoms (for units see Table I)
FFA
l-"C-palmitic acid
16-"F-hexadecanoic acid*
17-18F-heptadecanoic acid*
17-34mCl-heptadecanoic acid
17-77Br-heptadecanoic acid
16-'31I-hexadecanoic acid
17-131I-heptadecanoic acid
16-'31I-hexadecanoic and
Animal
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
rat
dog
rat
rat
dog
Uptake
43% i.d. g"
41% i.d. g"
46% i.d. g~
17% i.d. g-
17% i.d. g-
56% Ld. g"
37% Ld. g-
40% i.d. g"
48% i.d. g-
8% i.d. g " '
4-2% i.d.
0-39% kg d. g-
6-59% i.d.
0-57% kg d. g-
Time (min)
<O5
• 025
1-0
<0-5
<0-5
0-25-0-5
0-75
0-5
0-5
1-5
5
5
1
1
 5
Ref.
6
13
13
6
6
15
6
16
17
18
19
20
21
22
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Table 5 Myocardial uptake of various unsaturated FFAi (for abbreviations see Table I)
FFA
16-131I-hexadecanoic acid
16-131I-9-hexadecenoicacid E
Z
l6-82Br-9-hexadecenoic acid
16-l31I-9-hexadecenoic acid
14-l31I-7-tetradecynoic acid
15-l31I-9-pentadecynoic acid
16-131l-9-hexadecynoic acid
18-l31I-9-octadecynoic acid
20-'3 ' 1-12-eicosynoic acid
16-l31I-hexadecanoic acid
14-131-9-hexadecynoic acid
Animal
mouse
mouse
mouse
mouse
mouse
dog
dog
mouse
mouse
mouse
mouse
mouse
dog
dog
Uptake
56%i.d.g-'
55% id. g - '
51% i.d. g - l
39%i.d. g - '
27%i.d.g-'
77%
2-4% i.d.
19% i.d. g"1
30%i.d. g - '
43% i.d. g - '
32% i.d. g-1
39% i.d. g"1
0 5 7 % k g d . g - '
0-49% kg d. g"1
Time (min)
0-25-0-5
0-5-0-75
0-5-0-75
0-0-25
05
5
025
0-O25
0-O25
0-O25
0-O25
5
5
Ret
15
15
15
15
23
3
19
17
17
17
17
17
22
22
triple bond is different, probably increasing the
polarity of the molecule.
The influence of chain length—odd/even effect?
The fatty acids which are mostly used by the body
have 16 or 18 carbon atoms. As can be seen
(Table 6(I7-20)) the myocardial uptake of these FFAs
is also highest. Obviously the uptake mechanism,
which governs the transport of FFAs from the blood
into the cells has a preference for these long-chain
FFAs.
The higher uptake of FFAs for longer chains can
also be seen with the unsaturated compounds
(Table 5(17)) although the interpretation here is
obscured by the influence of the triple bond. And the
same has been observed for FFAs where Te is one of
Table 6 Uptake of FFAs in the heart with varying length of the C-chain—omega labelled, except '""Te (for abbreviations
see Table I)
FFA
1 l-123I-undecanoic acid
13-l23I-tridecanoic acid
16-125I-hexadecanoic acid
19-'23I-nonadecanoic acid
22-l25I-docosanoic acid
27-12'I-heptacosanoic acid
13-l3lI-tridecanoic acid
14-131I-tetradecanoic acid
15-1311-pentadecanoic acid
16-131I-hexadecanoic acid
17-131I-heptadecanoic acid
18-13lI-octadecanoic acid
20-l31I-eicosanoic acid
8-82Br-octanoic acid
1 l-"Br-undecanoic acid
12-82Br-dodecanoic acid
123mTe-9-telluraheptadecanoic acid
123Te-9-telluratridecanoic acid
15-{13lI-4-iodophenyl)pentadecanoic acid (I-PPA)t
5-{13lI-4-iodophenyl)valeric acidf
Animal
rat
rat
rat
rat
rat
rat
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
mouse
rat
rat
mouse
mouse
Uptake
035% kg d. g"
030% kg d. g-
039% kg d. g"
1-O0%kgd.g-
079% kg d. g-
.025% kg d. g-
41% i.d. g" '
42% i.d. g - '
47% i.d. g"1
56% i.d. g"1
48% i.d. g"1
32% i.d. g - '
36%i.d.g"'
20% i.d. g"1
45% i.d. g" '
41% i.d. g"1
5-5% i.d. g - '
1-6% i.d. g- 1
35%i.d.g- '
15% i.d. g - '
Time (min)
5
5
5
5
5
5
075
075
050
O50
050
05-O75
O50
0
0
075
60
5
2-5
2-5
Ref.
20
20
20
20
20
20
17
17
17
17
17
17
17
17
17
17
24
24
25
25
t 'I-PPA: 15-{*I-4-iodophenyl)pentadecanoic acid with *I for radioiodine.
t Valeric acid = pentanoic acid.
Uptake of labelled FFAs
the links in the carbon chain (Table 6(24)). Observa-
tions with omega-bromo-substituted FFAs and
omega-halophenyl-substituted compounds (Table
6(I7-25)) also confirm this point.
In nature, practically all FFAs occur with an even
number of C-atoms. The beta-oxidation metabolism
of FFAs breaks these compounds down by chopping
off two C-atoms (an acetyl-group) at a time(26). If
there is an odd number of C-atoms the last unit will
have three C-atoms (propionyl group). In the
catabolic behaviour a clear odd/even effect has been
observed with 1 8F as the label'13'.
Although it is difficult to establish because of the
large standard deviations in the results and because
one can hardly compare the results of one group
with those of another, one may tentatively read from
the data presented that FFAs with an odd number of
C-atoms in the chain are taken up by the heart to a
lesser extent than even numbered ones. It must be
borne in mind that the omega-iodine label in the
case of FFA uptake can be treated as a methyl
group. Therefore an omega-iodinated FFA must, for
the sake of this argument, be considered as having a
C-chain with one extra atom. The reasoning is
further complicated by the fact, that the odd/even
effect is necessarily accompanied by a change in the
length of the C-chain. We have shown an odd/even
effect more clearly in the dog*19).
Omega-phenyl substituted FFAs
Because myocardial elimination of FFAs is fairly
fast (half life values in man ~ 10-20 min) resulting
(with radiohalogenated FFAs) in high blood levels
and thus in high background levels in scintigraphy,
several structural alterations in the C-chain have
been made to prolong myocardial residence time and
to reduce (blood) background levels.
One approach has been to introduce a phenyl
group in the omega-position and then label this
aromatic ring with the radiohalogen. The radio-
halogen will go to the ortho- (or 2-) or para- (or 4-)
position. It was immediately established (in the case
of omega-phenyl-pentadecanoic acid), that ortho
substitution led to less uptake than para substitution
(Table 7)(27). The para compound was taken up by
the heart to about the same extent, as 'normal'
omega-iodinated FFAs (Table 7(27"33)) although
once again results from different papers are
impossible to compare.
The uptake of the bromo-substituted phenylpenta-
decanoic acid was the same as for the iodo-
compound (Table 7<27)) indicating that the halogen
label did not influence the polarity of the C-chain to
an appreciable extent.
On the contrary, when the phenyl group was
coupled to the C-chain via an electron-rich linkage
Table 7 Myocardial uptake of omega-phenyl- and omega-vinyl-FFAs (for abbreviations see Tables 1 and 6)
FFA Animal Uptake Time (min) Ref.
17-I-heptadecanoic acid
I-PPA
15-{'23I-2-iodophenyl)pentadecanoic acid
14-(123I-4-i<xlophenyl)tetradecanoic acid
Br-PPAf
15-(8JBr-2-bromophenyl)pentadecanoic acid
1 3
' I-12-N(4-iodophenylsulphonamide)dodecanoic acid
131I-1 l-N(4-iodophenylsulphonamide)undecanoic acid
*I-E-18-iodo-17-octadecenoic acid
mouse
dog
dog
dog
mouse
mouse
rabbit
rabbit
rat
rat
rat
mouse
rat
mouse
mouse
mouse
mouse
mouse
rat
37% i.d. g"1
4-2% i.d.
4-5% i.d.
4-5-6-0% i.d.
32% i.d. g- 1
28-35% i.d. g" '
032% i.d. g"1
082%kgd .g~ 1
4-5% i.d. g"1
17% i.d. g"1
3-0% i.d. g"1
18% i.d. g"1
2-7% i.d. g"1
30% i.d. g - '
33% i.d. g- 1
22% i.d. g" '
027% i.d. g - '
047% i.d. g"1
317% i.d. g-1
075
5
5
3
20-28
9
9
1
1-5
5
3
5
3
05
3
5
5
5
6
19
19
32
27
28
28
28
29
30
31
27
31
27
33
27
34
34
35
t *Br-PPA: 15-(*Br-4-bromophenyl)pentadecanoic acid with *Br for radiobromine.
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such as in p-iodophenyl-sulphonamide alkanoic acids
(Table 7(34)) no myocardial uptake was observed.
3-methyl pentadecanoic acid shows relatively high
uptake (Table 8(31)).
Omega-vinyl substituted FFAs
Another structural feature which (from the
chemical point of view) belongs under the same
heading (in stabilizing the iodine on the C-chain) as
an omega-vinyl group, would be the omega-vinyl
group, labelled with iodine trans with respect to the
rest of the C-chain. This leads to uptake in the heart
comparable to that of omega-phenyl substitution
(Table 7(35)).
Methyl-branching of the carbon-chain
Another structural feature for prolonging
myocardial residence time of FFAs could be the
introduction of a methyl group in the carbon chain,
because this would block beta oxidation.
This seems to work reasonably well for 14C and
" C labelled FFAs (Table 8 (736)), but far less so for
omega-iodinated beta-methyl compounds'37 '. In the
former case uptake remains normal, whereas in the
latter case the 5-min retention period is considerably
less than for the corresponding straight chain
compounds.
The combination of para-phenyl substitution and
a beta methyl group also does not work particularly
well: again heart uptake is relatively low
(Table 8<37)). However, here the relative shortness of
the C-chain may play an important role, because the
corresponding longer chain para-iodophenyl-
Tellura fatty acids
Apart from the former mentioned changes in
FFA-structure, in which the C-chain remained
essentially intact, another approach for prolonging
myocardial half lives of FFAs has been to insert a
tellurium atom (Te) as a link in the C-chain. This
also blocks the normal beta-oxidation mechanism
(Table S*"4'24'38"42'). For high uptake values the
usual C-chain length of 16 or 18 carbons was
optimal.
Obviously the position of the Te in the C-chain is
also of great influence on heart uptake: high uptake
is only found if the Te is in the middle of the chain;
positions too close to either end give essentially
lower uptake.
Because of the unfavourable radiation charac-
teristics of 123raTe (physical half life 120 days), the
tellurium concept has been extended in that inactive
Te is being inserted in the chain, whereas the chain is
omega-labelled with radioiodine.
If the iodine is simply coupled to the carbon chain
the iodine seems to be cut off directly'40' and thus
the tellurium-radioiodine concept was extended
once more to include stabilization of the radioiodine
as the para iodophenyl-'41' or the trans
iodovinyl-'38-421 group. This was shown to work
reasonably well.
Again it turned out that the Te must be in the
middle of the C-chain to get the higher uptake
Table 8 Uptake in the heart of methyl-substituted FFAs (for abbreviations see Tables I and 6)
FFA Animal Uptake Time (min) Ref.
16-14C-palmitic acid
l-14C-3-methylheptadecanoic acid
l-"C-3-methylheptadecanoic acid
16-'"I-hexadccanoic acid
13-1J5I-3-methyltridecanoic acid
16-123I-3-methylhexadecanoic acid
14-l25I-3,3'-dimethyltetradecanoic acid
' " I -PPA
8-0"I-4-iodophenyl)-3-methyloctanoic acid
' " I - P P A
15-{l2'I-4-iodophenyl)-3-methylpentadecanoic acid
14-(l23I-4-iodophenyI)tetradecanoic acid
14-025I-4-iodophenyl)-3-methyltetradecanoic acid
rat
rat
rat
rat
dog
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
2-6% i.d. g - '
4-3% i.d. g - 1
2-9% i.d. g - '
2-0% i.d.
8-3% i.d.
0-39% kg d. g-
0-13%kgd.g-
0-34% kg d. g-
003% kg d. g
0-69% kg d. g
0-17%kgdg-
2-98% i.d. g"1
4-62% i.d. g"1
2 72% i.d. g - 1
1-71% i.d. g"1
- 1
- 1
- i
- I
- 1
i
5
15
30
30
5
5
5
5
5
5
5
5
5
5
7
7
36
36
36
37
37
37
37
37
37
31
31
31
31
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Table 9 Myocardial uptake of FFAs with tellurium as a link in the carbon chain, including omega-phenyl and omega-vinyl
compounds (for abbreviations see Table 1)
FFA Animal Uptake Time (min) Ref.
V
13-i"Te.telluraheptadecanoic a cjd9-'"Te-telluraheptadecanoic ^ j
ll-'23Te-telluraheptadecanoic acid
6-l23mTe-telluraheptadecanoic acid
9-123"Te-tellurapentadecanoic acid
9-123mTe-telluratridecanoic acid
6-123mTe-telluratridecanoic acid
17- n 3mTe-tellura-9-heneicosenic acid
17-123mTe-tellura-9-octadecenoic acid
17-1J3mTe-tellura-9-nonadecenoic acid
18-methyl-17-'"Te-tellura-9-nonadecenoic acid
3- l jMTe-telluranonadecanoic acid
17-'2 5I-iodo-9-telluraheptadecanoic acid
17-iodo-9-123aTe-telluraheptadecanoic acid
l-l4C-oleic acid
15-(123I-4-iodophenyl)-6-tellurapentadecanoic acid
18-l25I-iodo-5-tellura-17-ocladecenoic acid*
18-123I-iodo-7-tellura-17-octadecenoic acid*
18-123I-iodo-9-tellura-17-octadecenoic acid*
18-l23I-iodo-l 1-tellura-l7-octadecenoic acid*
18-l23I-iodo-13-tellura-17-octadecenoic acid*
18-iodo-' 23°Te-tellura-13-17-octadecenoic acid
rat
rat
mouse
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
rat
1 1 % i.d. g"
3-7% i.d. g-
3O5% i.d. g"
3-3% i.d. g-
5-5% i.d. g"
38% i.d. g"
3-4% i.d. g"
4 1 % i.d. g"
44% i.d. g"
12% i.d. g"
1-6% i.d. g"
2-7% i.d. g"1
unstable in vivo
0 20% i.d. g"1
0-11% i.d. g~'
018% i.d. g"1
2-4% i d. g"
1-4% i.d. g"
2-2% i.d. g"
3 4% i.d. g"
5-9% i.d. g"
3-0% i.d.
4-6% i.d. g"1
3-5% i.d. g" '
5-2% i.d. g"1
3-6% i.d. g"1
1-8% i.d. g"1
2-0% i.d. g-
5
30
5
30
60
5
5
60
5
30
5
5
2
2
30
5
5
5
30
5
60
60
60
60
38
14
14
24
24
24
24
24
24
24
24
24
39
39
39
39
40
40
40
12
41
41
41
38
42
42
38
38
* The double bond in the 17-position is the vinyl group.
values. Interestingly, once Te was inserted in
18-iodo-tellura-l 7-octadecenoic acid in the
13-position, uptake was far less than for the
5-position(38>42): thus if the Te is close to the
carboxyl group it has a less detrimental effect on
uptake values.
Problems
It is difficult to reach any general conclusions from
the present knowledge on FFA uptake because of the
inconsistency of the results, either from a comparison
of data from different groups or even from one and
the same group. Also the use of different units to
express the (relative) uptake values, without giving
sufficient particulars to convert the data confuses the
issue. Units used are % (extraction fraction), % of
injected dose per total organ, % of injected dose per
gram of tissue, % kg dose per gram of tissue (which
includes the body weight) (see the various tables in
this review), ECAT units(2) and cpm g" ' ( U 4 3 » .
Further confusion stems from the use of different
experimental animals: mice, rats, rabbits, guinea pigs,
dogs, calves and human beings have been studied.
Particularly, the data on the small animals (mice,
rats) are often reported from the fifth minute after
injection, which means that no true maximum
uptake values are given; the myocardial half life of
FFAs in mice and rats is less than 1 min. Longer
retained activity is associated mainly with the lipid
fractions in the cell.
As FFAs are very important metabolic substrates
for energy production, nutrition and medication can
obviously be expected to influence FFA metabolism.
Nevertheless the impact on myocardial uptake has
hardly been studied (Table ltf44"48*).
It has been postulated that fasted rats showed
higher heart uptake of I23I-16-iodohexadecanoic
acid than non-fasted animals'441. Sodium pento-
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myocardiat uptake of FFAs (for abbreviations
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see Table
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1)
Ref.
123I-16-iodohexadecanoic acid
9-123Te-telluraheptadecanoic
 acid
1
 "I-16-iodo-9-hexadecenoic
131l-16-iodo-9-hexadecenoic acid
1 3
' I-17-iodoheptadecanoic acid
rat
rat
rat
dog
dog
dog
dog
dog
fasting as compared with non-fasting
sodiumpentobarbital anaesthesia in
fasting animal
fasting
high fat diet
heparin + intralipid
heparin alone
glucose + insulin + K
betablockade with pindolol
[control
beta blockade with pindolol
beta blockade with metoprolol
beta blockade with timolol
beta blockade with propranolol
[control
43% increase
94% decrease
5-4% i.d.
6-2% i.d.
increase
no effect
increase
1-2% i.d. (5 min)
2-9% i.d.
2-5% i.d.
2-4% i.d.
2-7% i.d.
3-8% i.d.
4-2% i.d. (5 min)
44
44
45
45
46
46
46
47
47]
48
48
48
48
48]
barbital anaesthesia decreased tracer uptake
especially in non-fasted animals. The fasting effect
was not found with 123™Te-9-tellura-heptadecanoic
acid(45).
Treatment with heparin plus intralipid or with
glucose plus insulin plus potassium increased
myocardial accumulation of 123I-16-iodo-
9-hexadecenoic acid in the heart of the dog. Heparin
along had no effect'46*.
The beta blocker pindolol decreased uptake of this
tracer'471. Treatment with beta blockers also reduced
the uptake of 17-iodoheptadecanoic acid(48).
Thus data on the influence of nutrition and
medication are notably scanty and as yet allow for
no conclusions to be drawn.
Conclusions
Although a great many problems remain to be
solved, some general conclusions can be drawn:
Myocardial uptake is highest for the long-chain
FFAs with a carbon chain of 16 or 18 C-atoms.
Differences in uptake as a consequence of the
number of C-atoms being odd or even (odd
numbered FFAs are taken up to a lesser extent)
require further study.
Branching of the chain by introduction of a
methylgroup or the bigger halogens reduces
myocardial uptake. The small fluorine atom only has
an effect on uptake in the 2-position (beside the
carboxyl group) because of its influence on the acid
strength.
Substitution at the end of the C-chain reduces
uptake only when it results in higher polarity of the
molecule.
A double bond in the carbon chain [either in the
middle or at the end (omega-vinyl-)] does not
appreciably influence uptake in the heart, whereas a
triple bond causes appreciable reduction.
The replacement of one of the C-atoms of the
chain by a tellurium atom reduces uptake, once the
Te is too close to either end of the molecule; a Te in
the middle leaves uptake essentially unaffected.
Myocardial uptake of FFAs has been considered
to proceed by passive diffusion. However, this would
not account for all observed selectivities, the
structure-activity relationships described above. It
seems more likely that two mechanisms operate: (a)
passive diffusion, favouring the more lipofilic, long-
chain FFA, which is reduced once the molecule is
made more polar by substitution and (b) a carrier
mediated mechanism, which favours FFAs with an
appropriate length of 16 or 18 C-atoms.
An impressive number of various FFAs have now
been synthesized and used in various biological
experiments. In our opinion there is at present no
need for more variations on this theme, but the
available compounds must be used to do the
appropriate biological research. In this respect the
search for better uptake characteristics seems of less
importance than understanding the dynamic
behaviour of the favoured compound; higher uptake
can hardly be expected, considering the above-
mentioned structure-activity relationships, whereas
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the importance of (very) long retention times is a
question of interpretation. Unless a compound can
be found which depicts reversibly ischaemic areas in
the heart at rest (without exercise), FFAs do not
present an improvement with regard to 2O1T1-
thallium for the localization of ischaemia. But
possibly a fair understanding of dynamic FFA
behaviour under normal and pathological conditions
may turn radiolabelled FFAs into a useful diagnostic
tool.
In further biological research, more unity in the
execution of the experiments and the presentation of
the data would be advantageous. We have argued<48)
that the uptake in % of injected dose per total heart
is more relevant than, e.g. the more used % of
injected dose per gram of organ, but whatever ones
opinion on this, all relevant data should be given, to
enable the results in one favoured set of units to be
converted to another.
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